|
US11608343B2
(en)
*
|
2020-04-24 |
2023-03-21 |
Boehringer Ingelheim International Gmbh |
Substituted pyrimido[5,4-d]pyrimidines as HER2 inhibitors
|
|
TW202214641A
(zh)
|
2020-06-30 |
2022-04-16 |
美商艾瑞生藥股份有限公司 |
Ｈｅｒ２突變抑制劑
|
|
EP4323356A1
(en)
|
2021-04-13 |
2024-02-21 |
Nuvalent, Inc. |
Amino-substituted heterocycles for treating cancers with egfr mutations
|
|
PE20250118A1
(es)
|
2021-06-26 |
2025-01-16 |
Array Biopharma Inc |
Inhibidores de mutacion de her2
|
|
WO2023081637A1
(en)
*
|
2021-11-02 |
2023-05-11 |
Enliven Therapeutics, Inc. |
Fused tetracyclic quinazoline derivatives as inhibitors of erbb2
|
|
CN114031619A
(zh)
*
|
2021-12-17 |
2022-02-11 |
山东汇海医药化工有限公司 |
一种图卡替尼中间体的制备方法
|
|
CN114621221B
(zh)
*
|
2022-03-12 |
2022-10-11 |
陕西海辰风扬医药科技有限公司 |
妥卡替尼关键中间体及其制备方法
|
|
JP2025509995A
(ja)
|
2022-03-28 |
2025-04-11 |
江蘇恒瑞医薬股▲ふん▼有限公司 |
含窒素複素環系化合物、その調製方法及びその医薬的使用
|
|
CN117384162A
(zh)
*
|
2022-05-17 |
2024-01-12 |
浙江文达医药科技有限公司 |
选择性her2抑制剂
|
|
WO2024027695A1
(zh)
*
|
2022-08-04 |
2024-02-08 |
微境生物医药科技(上海)有限公司 |
作为her2抑制剂的化合物
|
|
US20240132521A1
(en)
|
2022-08-22 |
2024-04-25 |
Iambic Therapeutics, Inc. |
Compounds and methods for modulating her2
|
|
EP4687905A1
(en)
|
2023-03-30 |
2026-02-11 |
Revolution Medicines, Inc. |
Compositions for inducing ras gtp hydrolysis and uses thereof
|
|
WO2024229019A1
(en)
*
|
2023-05-01 |
2024-11-07 |
Enliven Inc. |
Polymorphic forms of (e)-l-((10s)-4-((4-([l,2,4]triazolo[l,5-a]pyridin- 7-yloxy)-2-fluoro-5-methylphenyl)amino)-7,8,10,ll-tetrahydro- 9h-6,10-methanopyrimido[4',5':5,6]pyrido[3,2-b][l,4,7]oxadiazonin-9- yl)-4-(dimethylamino)but-2-en-l-one
|
|
AU2024265078A1
(en)
|
2023-05-04 |
2025-12-11 |
Revolution Medicines, Inc. |
Combination therapy for a ras related disease or disorder
|
|
CN116903615A
(zh)
*
|
2023-06-21 |
2023-10-20 |
江苏丽源医药有限公司 |
一种妥卡替尼及其中间体的制备方法
|
|
IL326136A
(en)
|
2023-08-07 |
2026-03-01 |
Revolution Medicines Inc |
RMC-6291 for use in the treatment of a disease or disorder associated with the RAS protein
|
|
WO2025034912A2
(en)
|
2023-08-07 |
2025-02-13 |
Cogent Biosciences, Inc. |
Compounds for fgfr inhibition
|
|
US20250154171A1
(en)
|
2023-10-12 |
2025-05-15 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2025171296A1
(en)
|
2024-02-09 |
2025-08-14 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2025240847A1
(en)
|
2024-05-17 |
2025-11-20 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
US20250375445A1
(en)
|
2024-06-07 |
2025-12-11 |
Revolution Medicines, Inc. |
Methods of treating a ras protein-related disease or disorder
|
|
WO2025265060A1
(en)
|
2024-06-21 |
2025-12-26 |
Revolution Medicines, Inc. |
Therapeutic compositions and methods for managing treatment-related effects
|
|
WO2026006747A1
(en)
|
2024-06-28 |
2026-01-02 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026007878A1
(zh)
*
|
2024-07-01 |
2026-01-08 |
北京鞍石生物科技股份有限公司 |
稠环化合物及其制备方法和应用
|
|
WO2026015796A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026015825A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Use of ras inhibitor for treating pancreatic cancer
|
|
WO2026015790A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026015801A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026050446A1
(en)
|
2024-08-29 |
2026-03-05 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026072904A2
(en)
|
2024-09-26 |
2026-04-02 |
Revolution Medicines, Inc. |
Compositions and methods for treating lung cancer
|